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In vivo PEG modification of vascular surfaces for
targeted delivery
Timothy E. Deglau, PhD,a,b Timothy M. Maul, PhD,a,b,c Flordeliza S. Villanueva, MD,b,d and
William R. Wagner, PhD,a,b,c,e Pittsburgh, Pa
Objective: Thrombosis and restenosis remain problematic for many intravascular procedures. Previously, it has been
demonstrated that modifying an injured vascular surface with a protein-reactive polymer could block undesirable platelet
deposition. As an added benefit, it would be advantageous if one could target therapeutics to the injured site. This study
investigates a site-specific delivery system to target microspheres to vascular surfaces modified with a reactive polyethylene
glycol tagged with biotin.
Methods: Rabbit femoral arteries were injured with a 2F embolectomy catheter. Modification of the vascular surface was
achieved using a channeled balloon catheter or small-diameter tube. Microspheres were injected intravenously through
catheterization of the ear vein. Polymer modification on the injured surface and delivery of microspheres was quantified
using epifluorescence microscopy at 0, 24, 48, and 72 hours.
Results: Polymermodification of the vascular surface could be achieved using a channeled drug delivery catheter or small-diameter
tube with similar results. Maximum polymer coverage occurred at 0 hours and decreased to 85% maximal at 24 hours, 72% at 48
hours, and 67% at 72 hours. The initial number ofmicrospheres permm2 binding tomodified, injured arteries was 304 versus 141
for the unmodified, damaged control (P< .01). At subsequent times, the number of adherent microspheres to modified, injured
arteries decreased by 50%, 70%, and 84% at 24, 48, and 72 hours, respectively; while nonspecific binding to unmodified, injured
arteries quickly decreased by 93%. Initialmicrosphere binding tomodified, healthy arterieswas 153microspheres/mm2 as opposed
to 26 microspheres/mm2 for the unmodified, healthy controls (P< .01).
Conclusions: Chemical modification of injured vessels following intravascular procedures can be readily accomplished in vivo to
create a substrate for targeted delivery systems. As a proof of concept, targeted microspheres preferentially adhered to polymer-
modified surfaces as opposed to injured, unmodified, or healthy vascular surfaces. (J Vasc Surg 2012;55:1087-95.)
Clinical Relevance:Clinical outcomes of intravascular procedures are often complicated by thrombosis and restenosis due
to vascular injury. These results demonstrate the feasibility of providing site-specific recognition signals for delivery of
agents to healthy and damaged vascular tissue, which could prove valuable in a variety of clinical settings where the
localization of therapeutics is desirable. In particular, the delivery of antimitotic or antithrombotic particulate pharma-
ceuticals or carriers to arterial lumens following angioplasty or endarterectomy, or chemotherapeutic agents to tumor
vasculature might be feasible.
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pDisruption of the endothelial layer during intravascular
procedures such as balloon angioplasty often leads to reste-
nosis. Exposure of a thrombogenic surface leads to platelet
and leukocyte activation, which contribute to thrombus
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doi:10.1016/j.jvs.2011.09.081ormation and inflammation.1 In addition, balloon infla-
ion can lead to dissections within the arterial wall, causing
mooth muscle cell injury. Factors released by platelets and
eukocytes, as well as direct injury, cause smooth muscle
ells to proliferate, migrate, and deposit more extracellular
atrix, resulting in neointimal hyperplasia.2,3 Stents have
educed, but not eliminated, the problem of restenosis, and
ave introduced new risks of stent thrombosis related to
elayed re-endothelialization, often requiring long-term anti-
latelet therapy. Thus, strategies to mitigate the cascade of
athophysiologic events that lead to restenosis and contribute
o stent thrombosis would have significant clinical value.
In the current study, a protein-reactive polymer, N-
ydroxysuccinimide-polyethylene glycol (NHS-PEG), was
mployed in an in vivo rabbit femoral artery model of
ascular injury to directly modify injured vascular surfaces.
he goal of the study was to demonstrate the potential for
olymer modification of the vascular surface to block acute
hrombosis and provide a site for the targeted delivery of
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April 20121088 Deglau et altherapeutics. The NHS reactive group covalently links with
primary amines, the most accessible being the epsilon
amine found on the amino acid lysine.4 A stable amide
bond is formed covalently linking the protein-reactive poly-
mer with a primary amine of a protein on a vascular sur-
face.5 Previous reports have demonstrated that modifica-
tion of vascular surfaces with a protein-reactive PEG forms
a molecular barrier preventing acute platelet and leukocyte
adhesion.6,7
In addition to blocking thrombosis at sites of vascular
injury, it would be advantageous to have a means of target-
ing intravenously injected agents to labeled vascular seg-
ments for further therapeutic benefit. This could be accom-
plished by the presence of a signalingmolecule, such as biotin,
on the nonreactive terminus of the PEGmolecule.NHS-PEG
biotin might thus modify vascular tissue and provide a site
for the targeted delivery of agents relying on the high affinity
between biotin and avidin (Ka  10
15 L/mol).4 Targeting
systems exploiting the strong interaction between biotin
and avidin have previously been explored as drug delivery
vehicles for tumors and whole organs.8,9 Our objective
here was to evaluate this concept (Fig 1) in a rabbit model
using avidin-coated microspheres to simulate particulate
drugs, liposomes, or vesicles targeted to PEG biotin-
modified arterial segments. The dependence of PEG-biotin
coverage on the delivery method and time after modifica-
tion were examined, as was the ability to target micro-
spheres to the modified vascular segment over a 72-hour
period.
METHODS
Surgical procedure. The animal studies were com-
pleted following approval by the University of Pittsburgh
Institutional Animal Care and Use Committee. This study
employed a rabbit femoral artery model to evaluate the
proposed modification and targeting system.6 Female New
Zealand White rabbits (Myrtle’s Rabbitry, Inc, Thompson
Station, Tenn) with an average weight of 4.25 kg were
Fig 1. Schematic of the proposed targeted delivery system. The
reactive polymer is covalently attached to the vascular surface
forming a molecular barrier, inhibiting platelet and leukocyte
adhesion. Targeted microspheres or cells will specifically adhere to
vascular surfaces labeled with the polymer. PEG, Polyethylene
glycol.anesthetized by intramuscular injection of 40 mg/kg ket- (mine and 5 mg/kg xylazine and maintained on inhaled
.5 to 2.5% isoflurane (Webster Veterinary, Sterling,Mass).
n ear vein was cannulated with a 22 G x 1-inch JELCO IV
atheter (Webster Veterinary), and a slow drip of lactated
inger’s buffer (Webster Veterinary) was administered
hrough a Venoset Microdrip IV set (Webster Veterinary).
he common femoral, saphenous, and popliteal arteries
ere exposed by dissection, andminor side branches off the
ommon femoral artery were ligated and removed.
UNDT Slim-Line aneurysm clips (Codman, Raynham,
ass) were placed on the common femoral, deep femoral
ranch, and on the popliteal arteries. An arteriotomy was
ade in the saphenous artery to allow access to the lumen
f the common femoral artery. Only one leg was used in
urvival studies to minimize trauma to the animal and allow
or adequate mobility for water and food intake. In acute
tudies, the same procedure was repeated on the other leg
f the animal to minimize the number of animals required.
Balloon injury. A 2F Fogarty embolectomy catheter
Edwards Lifesciences, Irvine, Calif) was inserted through
he arteriotomy in the saphenous artery until it reached the
lamp on the common femoral artery. The balloon was
nflated with air using a 1-mL slip-tip disposable tuberculin
yringe (Becton Dickinson [BD], Franklin Lakes, NJ) until
he vessel distended slightly. The inflated balloon was with-
rawn from the vessel until it reached the branch where the
opliteal and saphenous arteries emerge from the common
emoral artery. The balloon was deflated and the procedure
epeated three times to ensure vascular injury.10
Denudation of the endothelial layer and vascular injury
as confirmed in a small cohort of animals using 10 mg/kg
vans blue dye given intravenously 2 hours prior to eutha-
asia. Evans blue is an azo dye that binds with circulating
lbumin. An intact endothelium would serve as a barrier to
his protein-dye complex, but the complex adsorbs onto
enuded arterial segments, staining the surface a royal blue
olor.11 Both the injured common femoral artery and the
ninjured common femoral artery in the contralateral leg
ere harvested and inspected. Only femoral arteries injured
ith the embolectomy catheter appeared blue (data not
hown).
Arterial modification with PEG. Arterial lumen sur-
ace modification was accomplished using either a 0.63-mm
uter diameter Micro-Renathane (MR) tubing (Braintree
cientific, Braintree, Mass) or a 2.5-mm channeled drug
elivery balloon catheter (Remedy; Boston Scientific,
atick, Mass), which is a dual-lumen balloon and drug-
elivery catheter with 24 distinct channels on the outer
alloon surface, leading to a series of 100-m holes for
elivery of the therapeutic agent directly to the arterial wall
nd independent of the inflation of the balloon. The chan-
eled catheter was used to evaluate a more clinical ap-
roach, while the MR tubing was more practical for animal
nd proof-of-concept studies. The MR tubing or chan-
eled catheter was introduced into the common femoral
rtery through the saphenous arteriotomy and threaded
ntil the tip reached the clamp. Phosphate-buffered saline
PBS; Cambrex, Walkersville, Md) was added to NHS-
s
m
1
a
fl
w
f
a
2
p
a
i
s
L
1
h
o
V
b
m
W
i
t
w
c
w
o
e
F
v
H
u
i
t
i
i
I
s
f
o
i
t
(
t
t
f
o
q
(
r
D
d
b
a
JOURNAL OF VASCULAR SURGERY
Volume 55, Number 4 Deglau et al 1089PEG biotin (molecular weight [MW], 3400) or NHS-PEG
fluorescein (MW, 5000; Nektar Therapeutics, San Carlos,
Calif) to make 1 mL of a 10-mM solution and injected
through the port on the channeled catheter or using a 27 G
 half-inch needle (BD PrecisionGlide) inserted into the
end of the MR tubing to allow for perfusion of the polymer
into the vessel. The polymer solution was continuously
flushed through the vessel lumen for 45 seconds, after
which the MR tubing or balloon catheter was withdrawn,
and a previously placed ligature was tightened at the saphe-
nous artery branch point. When the total incubation time
for the polymer in the artery reached 1 minute, the aneu-
rysm clips were removed from the popliteal and common
femoral arteries to restore blood flow. The incubation time
and concentration of the infused solution were based on
previous in vitro studies.12 Control arteries were treated in
an identical manner except that the vehicle, PBS, was
perfused instead of the reactive polymer solution.
For control experiments in undamaged arterial seg-
ments, the tip of a 30 G x half-inch needle (BD Precision-
Glide) was bent to a 90° angle and inserted into the
common femoral artery lumen near the clamp. The poly-
mer was continuously flushed through the lumen of the
vessel and out the site of the arteriotomy for a period of 45
seconds. After addition of the polymer, the needle was
withdrawn, and a previously placed ligature was tightened
at the saphenous artery branch point. A small amount of
Avitene (Bard Davol, Inc, Warwick, RI) was placed at the
site of access to control bleeding. When the total incuba-
tion time for the polymer in the artery reached 1 minute,
the aneurysm clips were removed from the popliteal and
common femoral arteries to restore blood flow through the
femoral artery and remove any unreacted polymer. A subset
of arteries was treated in an identical manner except that the
vehicle, PBS, was added instead of the reactive polymer
solution.
Modified and control vessels from injured and unin-
jured animals were harvested at 0, 24, 48, and 72 hours
postoperatively (n  4-6 animals for each time point).
For nonacute studies, surgical sites were closed with 2-0
Vicryl sutures (Ethicon, Somerville, NJ), and the animals
recovered. Intramuscular injections of 1 mg/kg keto-
profen and 100 mg cefazolin (Webster Veterinary) were
administered twice daily until the animals were eutha-
nized.
Targeting of microspheres. A deglycosylated form of
avidin, NeutrAvidin, which has similar biotin binding char-
acteristics and lower nonspecific binding, was utilized in
these studies as a model of targeted drug delivery vehicles.
All microspheres were delivered to the peripheral circula-
tion through a cannulated ear vein. In the case of the
0-hour time point, intravenous access was already estab-
lished at the beginning of the surgical procedure, which
permitted administration of the microspheres. For the ex-
tended time points, the animals were anesthetized and an
ear vein catheterized as described previously in the Surgical
Procedure section. A bolus of 4.80 108 particles of 1-m
yellow-green fluorescent NeutrAvidin-labeled micro- npheres (Fluospheres; Molecular Probes, Eugene, Ore) in 1
L of PBS was injected over a period of 30 seconds via an
8 G  1.5-inch needle (BD PrecisionGlide) inserted into
n access port on the Venoset Microdrip IV set and then
ushed with lactated Ringer’s solution. The microspheres
ere allowed to circulate in the bloodstream of the rabbit
or 1 hour before the vessels were harvested as described
bove.
Specimen collection. Animals were maintained on
.5% isoflurane. Amidline incision below the rib cage to the
elvic region was used to expose and isolate the vena cava
nd aorta from the surrounding tissue. The isoflurane was
ncreased to 5% and the animals euthanized with a super-
aturated potassium chloride (KCl) solution (Sigma, St.
ouis, Mo). The aorta was cannulated with an 18 G 
-inch IV catheter (JELCO; Webster Veterinary), and the
ind limb portion of the animals was flushed with 100 mL
f lactated Ringer’s through a Venoset IV set (Webster
eterinary). The vena cava was severed to allow the excess
lood and fluid to drain from the hind limb region, and 100
L of Shandon Glyo-Fixx (Thermo Electron Corporation,
altham, Mass) was administered to pressure fix the arter-
es for examination. Experimental and control femoral ar-
eries were explanted from the rabbit after fixation along
ith the unmodified carotid arteries, which served as the
ontrol for acute experiments where both femoral arteries
ere modified. Excess tissue was removed from the exterior
f the arteries, which were then filleted lengthwise to
xpose the lumen. Minutien pins (Fine Science Tools,
oster City, Calif) were used to secure the edges of the
essel to pink dental wax (Electron Microscopy Sciences,
atfield, Pa) with the lumen facing upward for evaluation
sing epi-fluorescence microscopy.
Fluorescence microscopy of samples. Fluorescence
ntensity of the surface deposited polymer in the modifica-
ion experiments and quantification of microsphere bind-
ng in targeting experiments were performed using an
nverted fluorescence microscope (Axiovert; Carl Zeiss,
nc, Thornwood, NY). Micrographs of the explanted ves-
els were taken at the same exposure at 1-mm increments
rom the saphenous artery branch to the site of the clamp
n the common femoral artery. The average fluorescence
ntensity of the polymer (490-nm emission, 514-nm exci-
ation) was measured for each image with IP Lab software
Scanalytics Inc, Billerica, Mass) to determine the persis-
ence of the polymer modification over time. Quantifica-
ion of the number of adherent microspheres was per-
ormed on images collected at excitation/emission spectra
f 505 nm and 515 nm, respectively.
Statistical analysis. Statistical analysis of the data ac-
uired from the vessel images was performed in SPSS
version 13.0; SPSS Inc, Chicago, Ill). Data points are
epresented as mean values  standard deviation (st dev).
ifferences between control and treated groups for PEG
uration andmicrosphere targeting to balloon-injured rab-
it femoral arteries, at all time points, were evaluated using
two-way analysis of variance to determine statistical sig-
ificance. For microsphere targeting experiments to
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parisons were made using a Student’s t-test with P  .05
being considered statistically significant.
RESULTS
Arterial modification technique. Visual inspection
of the arterial specimens showed limited background fluo-
rescence for control vessels and similar patterns of staining
across treated arteries (Fig 2). No statistically significant
differences were found in the mean fluorescence intensity
(FU) of NHS-PEG fluorescein delivered to balloon-
injured arteries using the MR tubing (1241 FU) relative to
the channeled drug delivery catheter (1230 FU; Fig 3).
Control vessels showed little to no autofluorescence with a
mean fluorescence intensity of 69 FU (Fig 3). Since there
was no difference in the ability to deliver the polymer with
either technique, subsequent experiments evaluating the
duration of the polymer in the vessel or ability to target
microspheres to the polymer were completed using theMR
tubing. The MR tubing was selected because of its smaller
size in comparison to the channeled drug delivery balloon
catheter, which allowed for easier introduction into the
rabbit saphenous artery with fewer complications.
Duration of PEG coverage. In order to assess the
ability of the polymeric barrier to inhibit thrombosis and
Fig 2. Fluorescent micrographs of different techniques
glycol (PEG) fluorescein: (A) Vehicle (phosphate-buffere
(C) Remedy channeled drug delivery balloon catheter. Sserve as a site for the targeted delivery of therapeutics, it was important to establish the duration of the polymer on the
ascular surface postmodification. There was little to no
utofluorescence associated with denuded control vessels at
ny time point, with a mean fluorescence intensity of
nly 101 FU (Fig 4). The maximum fluorescence for the
olymer-modified vessels occurred at 0 hours with a mean
odify balloon-injured vessels with reactive polyethylene
ine [PBS]) control; (B)Micro-Renathane (MR) tubing;
ar is 100 m.
ig 3. Mean fluorescence intensity comparing the vehicle,Micro-
enathane (MR) tubing, and Remedy channeled drug delivery
alloon catheter delivery methods. Data are shown as fluorescence
ntensity (FU)  st dev.to m
d salntensity of 1529 FU, which then decreased to 1028 FU
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Volume 55, Number 4 Deglau et al 1091over the next 72 hours (Fig 4). There was a statistically
significant increase in fluorescent intensity over controls
(P .001), which decreased with time (P .05) in a linear
manner (FU  1500-7.1*time; P  .0001). Even though
the polymer remaining on the balloon-injured vessel de-
clined over time, 67% of the original fluorescence was
maintained at 72 hours (Fig 4).
In addition to evaluating the temporal maintenance of
the polymer, fluorescence intensity data from the images
along the entire length of the balloon-injured vessels mod-
ified with the fluorescent PEG were used to determine the
consistency of the polymer coverage for each time point.
There was some fluctuation of the mean intensity of the
fluorescent polymer over the length of the vessel, but there
was no significant effect with axial or circumferential vessel
position as determined by the two-factor analysis of vari-
ance (Fig 5).
Microsphere targeting. NeutrAvidin-coated micro-
spheres preferentially adhered to balloon-injured arteries
modified with PEG biotin as opposed to balloon-injured,
unmodified vascular surfaces at all time points evaluated
(Fig 6). A total of 304  64 microspheres/mm2 bound to
PEG biotin-modified balloon-injured femoral arteries as
compared with 141  80 microspheres/mm2 for the in-
jured, unmodified control at 0 hours (P  .001). The
number of adherent microspheres per mm2 for untreated,
balloon-injured rabbit femoral arteries decreased sharply
from 0 to 24 hours and then remained constant out to 72
hours, while the total number of adherent microspheres to
PEG biotin-modified, balloon-injured arteries gradually
decreased as the time postmodification increased, with
50  27 microspheres/mm2 remaining at 72 hours
(P  .001). The ability of the same targeting strategy to
target agents to healthy vascular tissue by the addition of
the reactive polymer or vehicle control to uninjured rabbit
Fig 4. Duration of polyethylene glycol (PEG) fluorescein on
balloon-injured rabbit femoral arteries after modification at 0, 24,
48, and 72 hours. Data are shown as fluorescence intensity (FU)
st dev with n  4 at all times and treatments, and the results are
significant with P  .001 for the time, treatment, and interaction.
PBS, Phosphate-buffered saline.femoral arteries was also assessed. NeutrAvidin-coated mi- Hrospheres were preferentially targeted to healthy vascular
issuemodified with the polymer as opposed to the unmod-
fied arteries (Fig 7). At 0 hours, a total of 153  46
icrospheres/mm2 bound to PEG biotin-modified
ealthy femoral arteries compared with 26  18 micro-
pheres/mm2 for the unmodified control at 0 hours
P .01; Fig 7). The total number of microspheres adher-
ng to PEG biotin-modified healthy tissue at 0 hours
153 46microspheres/mm2) was less than that seen with
he PEG biotin-modified, balloon-injured arteries (303 
5 microspheres/mm2).
ISCUSSION
Modifying vascular surfaces with a reactive PEG pro-
ides multiple options for preventing thrombosis or reste-
osis by serving as a molecular barrier, as well as providing
site for targeted drug delivery. Reactive PEG has previ-
usly been shown to form a molecular barrier on damaged
ascular surfaces7,13 as well as biomaterials6,14,15 to inhibit
latelet deposition, and we demonstrate that suitable levels
re maintained for 72 hours. Nanocoatings of hyaluron
nd chitosan deposited onto damaged vascular surfaces
ave also been used to inhibit platelet deposition, but they
ypically require multiple administrations of the polyelec-
rolytes.16 Likewise, concealment of extracellular matrix
igands with a PEGylated fibronectin, which interacts with
brillar collagens, to reduce platelet recognition, requires
0minutes to cover the injured vascular surface.17 Both the
yaluron and chitosan nanocoatings and PEGylated fi-
ronectin systems for inhibiting intravascular thrombosis
equire extended application periods or repeated adminis-
rations, which may be detrimental in time-sensitive proce-
ures. Hydrogel barriers formed by photopolymerization
ave also demonstrated an ability to inhibit thrombosis and
educe intimal thickening on injured vascular surfaces.
ig 5. Distribution of polyethylene glycol (PEG) fluorescein-
odified, balloon-injured rabbit femoral arteries along the vessel
ength at 0, 24, 48, and 72 hours as measured from the saphenous
rtery branch to the site of the clamp on the common femoral
rtery Data are shown as fluorescence intensity (FU)  st dev
n  4).owever, formation of the hydrogel barriers using photo-
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P  .001 for delivery time, treatment, and interaction.
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April 20121092 Deglau et alolymerization requires additional steps such as adsorption
f a photoinitiator on the injured vessel surface, flushing of
xcess initiator, administration of the hydrogel precursors,
nd adequate illumination (external or internal) to form the
el.18,19
Amajor advantage of the reactive PEG employed in the
urrent system from the standpoint of clinical implementa-
ion is that a single application could rapidly modify vascu-
ar surfaces (1 minute), potentially while an intervention
s being performed at the site using a channeled drug
elivery catheter. Establishing the consistency of the poly-
eric coverage along the entire length of the modified
essel was also important in evaluating the effectiveness of
he barrier to inhibit thrombosis or the signal to deliver
argeted therapeutics. The molecular barrier thickness
ould theoretically be manipulated by changing the molec-
lar weight or branching of the polymer molecule and thus
teries. (A) Unmanipulated carotid, (B) balloon-injured
tin-modified balloon-injured femoral arteries at 0 hours.
spheres adhering to control and PEG biotin-treated,
d 72 hours postmodification. Data are shown  st dev.Fig 7. Number of targeted microspheres adhering to control and
polyethylene glycol (PEG) biotin-treated healthy rabbit endothe-
lium in vivo at 0 hours. Data are shown st dev and the results areFig 6. Targeted microsphere adherence to rabbit femoral ar
control femoral artery, and (C) polyethylene glycol (PEG) bio
Scale bar is 100 m. (D) Quantification of targeted micro
balloon-injured rabbit femoral arteries in vivo at 0, 24, 48, aneduce some of these effects. Further, the PEG modifica-
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Volume 55, Number 4 Deglau et al 1093tion was sustained for at least 72 hours, and if one were to
assume that the linear trend continued, 25% of the polymer
would remain after 160 hours in vivo. The process by which
the PEG is removed from the surface is likely due to a
combination of the host response to the foreign material
that cleaves the modified protein, or the covalent PEG-
protein bond itself. Because the microsphere binding ca-
pacity was only 20% of the acute capacity by 72 hours, we
hypothesize that the further reduction in polymer availabil-
ity may be due to the nonlinearity of these types of binding
events, which have beenmodeled previously.20 A loss of the
microspheres through dissociation between streptavidin
and biotin is unlikely because of lengthy dissociation time
that contributes to the high affinity of the bond.21 Al-
though the use of PEG is associated with a reduction in
protein and platelet deposition,13,22 masking of the bind-
ing target for NeutrAvidin by fouling processes cannot be
dismissed. PEG hydrogels have also been synthesized to
release nitric oxide (NO) or YC-1, a benzyl indazole deriv-
ative, as therapeutic agents to reduce platelet adhesion and
smooth muscle cell proliferation after vascular injury.23,24
Therapeutics such as these and others might be delivered to
PEG-modified vascular sites using the targeting strategy
developed in this article.
Another method of inhibiting thrombosis and resteno-
sis at sites of arterial injury involves local administration of
drugs or gene therapy vectors to the injured vessels. Local
delivery of these agents can be accomplished using special-
ized catheters that employ passive, pressure-driven, electri-
cally, or mechanically enhanced diffusion for delivery.25,26
Using these catheters for direct delivery of the agents only
allows for one application or requires an indwelling line that
is prone to thrombosis. A single application of reactive PEG
that subsequently serves as a specific target for the drug or
therapeutic vector to be systemically injected over timemay
prove to be a more suitable system for long-term delivery.
Local delivery of therapeutics is also possible by target-
ing the molecules or using targeted carriers to direct the
therapy to specific vascular segments. While some studies
rely on local delivery,27,28 others incorporate additional
homing capabilities. One such method targets heparin or
low-molecular-weight heparin conjugated to antibodies
against cross-linked heparin, which is deposited at the site
of arterial injury, to reduce neointimal formation.29 Other
methods target microspheres or particles to selected vascu-
lar sites using antibodies to exposed surface markers. Hya-
luronmicrospheres conjugated to antibodies against E- and
P-selectin preferentially adhered to inflammatory vascular
sites and successfully delivered plasmid DNA.30 Similarly,
biodegradable particles conjugated to antibodies for E- and
P-selectin, ICAM-1, and VCAM-1 also showed targeting
to inflamed endothelium.31 In this balloon-injury model,
the attachment of NHS-PEG is intended here not to mod-
ify cells, but to modify the exposed basement membrane,
which is the source of acute thrombosis, and PEG has
previously been shown to interrupt platelet deposition and
acute thrombosis on this surface.6 Previous in vitro studies
indicate that it is possible to attain high surface densities of rhe PEG-biotin signaling molecule.12 In addition, thera-
eutic agents can be targeted to specific vascular segments
sing a tag on the end of the polymer molecule.12 Al-
hough there is a reduction in the available polymer over
ime, repeated delivery of therapeutic vehicles, such as
icrospheres, is still possible since not all of the sites will be
ccupied after the initial dose due to the limited concen-
ration of the microspheres in the boundary layer that
ccurs with systemic administration. Because the protein-
eactive PEG permits modification of both healthy endo-
helium and exposedmatrix following vascular injury, treat-
ent would not be dependent on the expression and
vailability of specific surface markers that are upregulated
n certain disease states. Systemic administration of the
eactive molecule itself, however, would not be feasible
ecause of the promiscuous nature of the reaction between
he PEG-NHS and surface amines, which would result in
EG modification of blood proteins encountered and any
ther molecules with free amine groups.
Drug-eluting stents, which release antimitotic agents
uch as sirolimus (CYPHER; Cordis Johnson & Johnson)
nd paclitaxel (TAXUS; Boston Scientific), have demon-
trated significant efficacy in reducing restenosis rates. Ran-
omized, controlled trials have demonstrated a reduction
n the need for repeat revascularization after coronary in-
erventions by 60% to 80% when using drug-eluting
tents.32 However, long-term results of the effects of drug-
luting stents are not well defined. As drug-eluting stents
re applied to more complex lesions, there have been
ncreasing occurrences of late stent thrombosis.33-35 The
olymer coating that serves as a reservoir for drug delivery
as also come under scrutiny. There are numerous reports
uggesting that a hypersensitivity reaction to the polymer
oating on the stents results in extensive inflammation of
he vessel wall.33,34,36,37 Modification of injured vascular
urfaces and stents with a PEG-reactive polymer provides
nother strategy that might be employed in conjunction
ith drug-eluting stents to further improve outcomes of
oronary interventions.38,39
There were several limitations in this technique that
hould be addressed in future studies. First and foremost,
his report represents a demonstration of the potential for
he technique and drug release or the therapeutic effects of
particular drug were not studied. The use of 1-m spheres
s a model delivery vehicle, while having a reduced foot-
rint for drag forces, also has a reduced binding density,
hich can limit their ability to withstand shear forces fol-
owing the initial binding event and may pose an issue for
ong-term drug-releasing systems.40 Nanoparticles might
rovide a better platform since they appear to be unaffected
y shear forces but would potentially have a smaller drug
ayload.41 The use of alternative ligand-receptor chemistry
lso might provide a means to improve upon the density of
articulate adherence.While the biotin-streptavidin bond is
xtraordinarily stable and well characterized,21 its use with
icroparticle delivery systems is limited in low-shear envi-
onments.42 Other particulate-surface interactions could
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1
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2
2
2
2
2
2
2
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April 20121094 Deglau et alalso be designed using lock and key mechanisms that have
more attractive kinetics, including aptamer technology.43
In summary, this study demonstrates that a protein-
reactive PEG can be used to modify healthy and injured
vascular segments. Furthermore, this polymer attachment
approach can be used as a target for the site-specific delivery
of microspheres to the labeled vascular tissue.Microspheres
are representative of a particulate drug or carrier that could
be loaded with various therapeutics designed to treat vari-
ous ailments. In cases of vascular injury, such as with
balloon angioplasties, carotid endarterectomies, or anasta-
moses, delivery of antithrombotics or antimitotics might
assist in inhibiting intimal hyperplasia.
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